Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | RNF4 | P78317 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PNLIP | P16233 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194415 | 0.87 | RXFP1 (0.54) | HPGDSMN1; SMN2ALDH1A1RXFP1MAPT | |
| SCHEMBL23966424 | 0.87 | RXFP1 (0.54) | HPGDSMN1; SMN2ALDH1A1TGM2NPC1 | |
| SCHEMBL21392904 | 0.85 | ALDH1A1 (0.55) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL219147 | 0.84 | KDM4E (0.66) | HPGDSMN1; SMN2ALDH1A1TGM2EPHX1 | |
| SCHEMBL7603741 | 0.83 | PKM (0.50) | SMN1; SMN2ALDH1A1RXFP1MAPTHTT | |
| SCHEMBL3199696 | 0.83 | RXFP1 (0.50) | HPGDSMN1; SMN2ALDH1A1TGM2EPHX1 | |
| SCHEMBL171438 | 0.82 | HPGD (0.71) | HPGDSMN1; SMN2ALDH1A1TGM2EPHX1 | |
| SCHEMBL19263968 | 0.82 | HPGD (0.61) | HPGDSMN1; SMN2ALDH1A1TGM2EPHX1 | |
| SCHEMBL8006359 | 0.82 | HPGD (0.66) | HPGDSMN1; SMN2ALDH1A1TGM2EPHX1 | |
| SCHEMBL7598040 | 0.82 | MTNR1B (0.51) | PGRHTTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072119-B | Cationic lignin-based flocculant and preparation method and application thereof | 大连工业大学 | 2020-09-11 | — | — | CN | claimed |
| CN-111072119-A | Cationic lignin-based flocculant and preparation method and application thereof | 大连工业大学 | 2020-04-28 | — | — | CN | claimed |
| CN-111072119-B | Cationic lignin-based flocculant and preparation method and application thereof | 大连工业大学 | 2020-09-11 | — | — | CN | disclosed |
| CN-111072119-A | Cationic lignin-based flocculant and preparation method and application thereof | 大连工业大学 | 2020-04-28 | — | — | CN | disclosed |
| CN-104803916-B | Hete rocyclic derivatives as SARM (SARMS) | 詹森药业有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-104803916-A | Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV | 2015-07-29 | — | — | CN | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
| EP-1817292-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| WO-2006055184-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | AR, NR5A1, NR5A2 | HPGD 705/4885SMN1; SMN2 4074/4885ALDH1A1 1240/4885 |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | HPGD 705/4885SMN1; SMN2 4074/4885ALDH1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.